文献速递炎症性肠病

溃疡性结肠炎患者报告结局正常时内镜改善与缓解的患病率

Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2019-11-22

该研究汇总英夫利西单抗、戈利木单抗、维得利珠单抗和托法替布临床试验的个体数据,分析溃疡性结肠炎患者报告结局(RBS和SFS)不同组合下内镜改善(MES 0/1)和缓解(MES 0)的患病率。结果显示RBS 0且SFS 0时,诱导后内镜改善81%、缓解29%,维持期改善91%、缓解57%(中心阅片数值更低)。

要点

  • 中心阅片的内镜改善和缓解率低于本地阅片。

核心结论

  • 约8/10直肠出血和排便频率正常的溃疡性结肠炎患者存在内镜改善,但仅约半数达到内镜缓解。

研究设计与样本

  • 汇总英夫利西单抗、戈利木单抗、维得利珠单抗和托法替布临床试验中积极干预组和安慰剂组的个体参与者数据,共2586例。

主要发现

  • 局部阅片下,诱导后RBS 0+SFS 0者内镜改善(MES 0/1)81%(95%CI 78-84),内镜缓解(MES 0)29%(26-33)。
  • 维持期RBS 0+SFS 0者内镜改善91%(87-93),内镜缓解57%(52-62)。

关键数值与推荐

  • 内镜改善定义为Mayo内镜子评分(MES)0或1,内镜缓解定义为MES 0。
  • 患者报告结局采用Mayo评分中的直肠出血子评分(RBS)和排便频率子评分(SFS)的不同组合。
  • 评估时间点为诱导治疗(6-8周)后和维持治疗(30-54周)期间。

临床怎么用

  • 症状缓解(RBS 0+SFS 0)不能等同于内镜缓解,约半数患者仍存在残余内镜活动,可能需考虑治疗调整。
  • 临床决策中应结合内镜评估,不应仅凭患者报告结局判断是否达标。

局限性

  • 数据来源于临床试验人群,可能不完全代表真实世界患者。
  • 本地阅片与中心阅片的内镜评分存在差异,影响患病率估计。
  • 未报告亚组分析的其他细节及混杂因素控制情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment targets for ulcerative colitis are evolving towards achievement of endoscopic improvement and remission in addition to symptom resolution. It remains to be accurately quantified what proportion of patients with symptom resolution have residual endoscopic activity that might warrant treatment modification. AIM: To quantify the prevalence of endoscopic improvement and remission amongst ulcerative colitis patients with various permutations of patient-reported outcomes. METHODS: Individual participant data from active intervention and placebo arms of clinical trials of infliximab, golimumab, vedolizumab and tofacitinib were pooled to estimate the prevalence of endoscopic improvement (Mayo endoscopic sub-score [MES] 0 or 1) and remission (MES 0) scores with various permutations of the rectal bleeding sub-score (RBS) and stool frequency sub-score (SFS) of the Mayo score, following induction (6-8 weeks) and maintenance (30-54 weeks) therapy. Subgroup analyses were performed by year of publication and centrally read endoscopy scoring. RESULTS: Data from 2586 trial participants were analysed. Using locally scored endoscopy, the prevalence of endoscopic improvement and remission was highest among participants with a RBS 0 + SFS 0 post-induction (MES 0/1:81%, [95% CI 78-84]; MES 0:29% [26-33]) and during maintenance (MES 0/1:91% [87-93]; MES 0:57% [52-62]). Prevalence estimates were lower for more recently performed trials (P < .01). In comparison to locally scored endoscopy, when using central endoscopy scoring, the prevalence of endoscopic improvement and remission was lower post-induction (MES 0/1 57% [50-64], P < .001; MES 0 15% [11-21], P = .09) and during maintenance (MES 0/1 74% [67-81], P = .001; MES 0 31% [24-38], P = .001) for participants achieving a RBS 0 + SFS 0. CONCLUSIONS: Approximately 8 of 10 patients with normalisation of rectal bleeding and stool frequency have improvement in endoscopic disease activity, whereas approximately only half of these patients have endoscopic remission.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Singh S, Jairath V, et al. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther. 2019. PMID: 31755121. doi:10.1111/apt.15577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。